Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, … Read more
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.059x
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has a cash flow conversion efficiency ratio of 0.059x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.10 Billion) by net assets (€35.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inner Mongolia Yitai Coal Co Ltd
SHG:900948
|
0.052x |
|
Atlas Corp
NASDAQ:ATCOL
|
0.083x |
|
Nantong Jianghai Capacitor Co Ltd
SHE:002484
|
0.075x |
|
VALIF
PINK:VALIF
|
N/A |
|
CITIC Pacific Special Steel Group Co Ltd
SHE:000708
|
0.086x |
|
Grandblue Environment Co Ltd
SHG:600323
|
0.085x |
|
Jiangsu Boqian New Materials Stock Co Ltd
SHG:605376
|
0.031x |
|
Under Armour Inc A
NYSE:UAA
|
0.194x |
Annual Cash Flow Conversion Efficiency for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2024)
The table below shows the annual cash flow conversion efficiency of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €37.77 Billion | €3.44 Billion | 0.091x | -18.54% |
| 2023-12-31 | €36.68 Billion | €4.10 Billion | 0.112x | -46.23% |
| 2022-12-31 | €33.64 Billion | €7.00 Billion | 0.208x | +14.89% |
| 2021-12-31 | €31.33 Billion | €5.67 Billion | 0.181x | +772.92% |
| 2020-12-31 | €28.21 Billion | €585.19 Million | 0.021x | -89.26% |
| 2019-12-31 | €25.99 Billion | €5.02 Billion | 0.193x | -14.27% |
| 2018-12-31 | €23.14 Billion | €5.22 Billion | 0.225x | +136.80% |
| 2017-12-31 | €19.26 Billion | €1.83 Billion | 0.095x | -33.96% |
| 2016-12-31 | €17.65 Billion | €2.54 Billion | 0.144x | -35.54% |
| 2015-12-31 | €8.68 Billion | €1.94 Billion | 0.224x | +1.31% |
| 2014-12-31 | €7.92 Billion | €1.75 Billion | 0.221x | +15.99% |
| 2013-12-31 | €7.02 Billion | €1.34 Billion | 0.190x | -- |